SAN DIEGO, May 22, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
that it has been awarded U.S. Patent No. 9671407, entitled DEVICES
AND METHODS OF CELL CAPTURE AND ANALYSIS. The patent covers the
broad use of antibodies for the capture of any target of interest
on any solid surface from any sample type. Targets of interest
include, but are not limited to, circulating tumor cells (CTCs),
sub-cellular vesicles, and exosomes shed by solid tumors into the
bloodstream.
Biocept now has 20 issued patents in the U.S. and key
international territories. The newly issued patent complements the
Company's intellectual property around its proprietary microchannel
platform for the ability to capture and interrogate a wide range of
biologic targets of interest.
"The granting of this patent significantly expands Biocept's
intellectual property rights regarding the use of 'cocktails' of
antibodies for the capture of any target of interest," said
Lyle Arnold, Ph.D., Chief Scientific
Officer at Biocept. "The expansion of this platform complements
nicely with Biocept's circulating tumor DNA (ctDNA) platform and
allows us to provide an expanded set of biomarker content to aid
physicians in making optimal treatment decisions for their cancer
patients."
Michael Nall, Biocept's President
and CEO, added, "Obtaining new intellectual property distinguishes
our platform's unique and novel features and, in this case, we
believe it offers the potential to drive additional value given the
broad implications of this patent. We continue to execute on our
business plan, as we leverage our proprietary liquid biopsy
technology to help physicians obtain actionable biomarker
information to improve treatment pathways and patient
outcomes."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
improve the outcomes of cancer patients, the utility and
effectiveness of our intellectual property protections, and our
ability to drive additional value of the Company, such statements
are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this news release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at www.sec.gov.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-awarded-us-patent-with-broad-claims-for-antibody-capture-of-targets-of-interest-on-any-solid-surface-including-ctcs-and-other-materials-shed-by-solid-tumors-into-blood-300461151.html
SOURCE Biocept, Inc.